¼¼°èÀÇ Ç÷ç¿Á¼¼Æ¾ ½ÃÀå º¸°í¼­(2025³â)
Fluoxetine Global Market Report 2025
»óǰÄÚµå : 1704374
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,339,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,163,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,987,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Ç÷ç¿Á¼¼Æ¾ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ¾ÈÁ¤ÀûÀÎ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2029³â¿¡´Â ¿¬Æò±Õ 4.7%ÀÇ ¼ºÀå·ü(CAGR)·Î 12¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ ÁßÀÇ ¼ºÀåÀº Á¤½Å°Ç°­ ÇÁ·Î±×·¥¿¡ ´ëÇÑ Á¤ºÎÀÇ ±¸»ó°ú ÀÚ±Ý Áö¿ø, Á¤½Å°Ç°­ ÁõÁøÀ» À§ÇÑ °øÁß º¸°Ç Ä·ÆäÀÎ, ¼Ò¼È¹Ìµð¾î Ç÷§Æû¿¡¼­ Á¤½Å°Ç°­ ¹®Á¦¿¡ ´ëÇÑ ³íÀÇ¿Í ÀÎ½Ä Áõ°¡, ¿Â¶óÀÎ ¾à±¹ÀÇ ºÎ»ó, Á¤½Å°Ç°­ ¹®Á¦¸¦ ¹Þ¾ÆµéÀÌ°í ´ëóÇÏ´Â ¹®È­Àû º¯È­ µî¿¡ ±âÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¤½Å°Ç°­ ¹®Á¦¸¦ ¹Þ¾ÆµéÀÌ°í ´ëóÇÏ´Â ¹®È­Àû º¯È­ µî¿¡ ±âÀÎÇÏ´Â °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â Á¶±â ¹ß°ßÀ» À§ÇÑ Áø´Ü ¹æ¹ýÀÇ ¹ßÀü, ¿ø°ÝÀÇ·áÀÇ ºÎ»ó, ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ ¹ßÀü, ½Å¾à °³¹ß ¹× ¾à¹° °³¹ß¿¡¼­ AI¿Í ¸Ó½Å·¯´×ÀÇ È°¿ë È®´ë, ¾à¹°À¯ÀüüÇÐÀÇ ¹ßÀü µîÀ» ²ÅÀ» ¼ö ÀÖ½À´Ï´Ù.

Á¤½ÅÁúȯ À¯º´·ü Áõ°¡´Â ÇâÈÄ Ç÷ç¿Á¼¼Æ¾ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¤½Å°Ç°­ Àå¾Ö´Â ÀÎÁö, Á¤¼­, Çൿ ±â´É¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÏ»ó »ýȰ¿¡ °íÅë°ú Àå¾Ö¸¦ ÃÊ·¡ÇÏ´Â ±¤¹üÀ§ÇÑ Áõ»óÀ» Æ÷ÇÔÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Áúȯ Áõ°¡ ¿äÀÎÀ¸·Î´Â »çȸÀû ¾Ð·Â, °æÁ¦Àû ¹®Á¦, »ýȰ½À°üÀÇ º¯È­, ÀÎÁö ¹× Áø´ÜÀÇ Çâ»ó µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. Ç÷ç¿Á¼¼Æ¾Àº ±âºÐ°ú °¨Á¤ Á¶Àý¿¡ Áß¿äÇÑ ³ú³» ¼¼·ÎÅä´Ñ ³óµµ¸¦ ³ô¿© Áõ»óÀ» ¿ÏÈ­ÇϹǷΠÁ¤½ÅÁúȯ Ä¡·á¿¡ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 11¿ù ¿µ±¹ Á¤ºÎ ÅõÀÚ ÀÇ·á ½Ã½ºÅÛÀÎ National Health Service°¡ ½Ç½ÃÇÑ Á¶»ç¿¡ µû¸£¸é 2022³â¿¡´Â 7-16¼¼ ¾Æµ¿ÀÇ ¾à 18.0%, 17-24¼¼ û¼Ò³âÀÇ ¾à 22.0%°¡ Á¤½ÅÀå¾Ö¸¦ ¾Î°í ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ƯÈ÷ 17-19¼¼ û¼Ò³âÀÇ Á¤½ÅÀå¾Ö °¡´É¼º À¯º´·üÀº 2021³â 17.4%¿¡¼­ 2022³â 25.7%·Î Áõ°¡Çß½À´Ï´Ù. °á°úÀûÀ¸·Î Á¤½ÅÁúȯ À¯º´·ü Áõ°¡´Â Ç÷ç¿Á¼¼Æ¾ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â Áß¿äÇÑ ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

Ç÷ç¿Á¼¼Æ¾ ½ÃÀåÀº ÇコÄɾî ÁöÃâ Áõ°¡·Î ÀÎÇØ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ Áõ°¡ÀÇ ¹è°æ¿¡´Â ÷´Ü ÀÇ·á ±â¼úÀÇ ºñ¿ë »ó½Â, °í·ÉÈ­, ¸¸¼ºÁúȯÀÇ È®»ê µîÀÇ ¿äÀÎÀÌ ÀÖ½À´Ï´Ù. ÀÇ·áºñ ÁöÃâÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Ç÷ç¿Á¼¼Æ¾°ú °°Àº ÀǾàǰ¿¡ ´ëÇÑ Á¢±Ù¼º ¹× ±¸¸Å ¿ëÀ̼ºÀÌ °³¼±µÇ¾î ¿ì¿ïÁõ ¹× ºÒ¾ÈÀå¾Ö Ä¡·á°¡ ÇÊ¿äÇÑ È¯Àڵ鿡°Ô Á¢±Ù¼º ¹× º¹¾à ¼øÀÀµµ °­È­¿¡ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ±× °á°ú, Àü¹ÝÀûÀÎ Á¤½Å°Ç°­ °á°ú°¡ °³¼±µÇ°í Àå±âÀûÀÎ ÀÇ·á ºñ¿ëÀÌ Àý°¨µÉ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2024³â 1¿ù ¹Ì±¹ ±¹¸³º¸°Ç¿ø(National Institutes of Health)Àº ¹Ì±¹ÀÇ ÀÇ·áºñ ÁöÃâÀÌ 2022³â 4.1% Áõ°¡ÇÑ 4Á¶ 5,000¾ï ´Þ·¯·Î 2021³â 3.2% Áõ°¡¿¡ ºñÇØ ¼ºÀå ¼Óµµ°¡ »¡¶óÁú °ÍÀ¸·Î ¿¹»óÇß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå ½ÃÀåÀÇ Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª¹ÙÀÌ·¯½º ¹× °æ±âȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ´ë±â¾÷°ú Çõ½ÅÀû ±â¾÷

Á¦32Àå ¼¼°èÀÇ ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÇÕº´°ú Àμö

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Fluoxetine, classified as a selective serotonin reuptake inhibitor (SSRI), is widely utilized as an antidepressant and for various psychiatric conditions. Its mechanism involves boosting serotonin levels, a neurotransmitter crucial for regulating mood, emotions, and behavior in the brain. Prescribed commonly for depression, fluoxetine aids in enhancing sleep, appetite, and energy levels among individuals with major depressive disorder.

Fluoxetine is available in diverse forms such as tablets, solutions, capsules, and syrups. Tablets, a solid oral dosage form, dissolve in the stomach upon ingestion and are administered to adults, children, and the elderly. This medication is frequently prescribed for conditions including obsessive-compulsive disorder, panic disorder, depression, and bulimia nervosa. It is utilized across various settings such as clinics and hospitals.

The fluoxetine market research report is one of a series of new reports from The Business Research Company that provides fluoxetine market statistics, including fluoxetine industry global market size, regional shares, competitors with a fluoxetine market share, detailed fluoxetine market segments, market trends and opportunities, and any further data you may need to thrive in the fluoxetine industry. This fluoxetine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The fluoxetine market size has grown strongly in recent years. It will grow from $0.99 billion in 2024 to $1.04 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to increased rates of depression and anxiety disorders, enhanced awareness and de-stigmatization of mental health issues, improved healthcare infrastructure, an aging global population, and the availability of cost-effective generic fluoxetine.

The fluoxetine market size is expected to see steady growth in the next few years. It will grow to $1.25 billion in 2029 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to government initiatives and funding for mental health programs, public health campaigns promoting mental well-being, increasing discussion and awareness of mental health issues on social media platforms, the rise of online pharmacies, cultural shifts towards accepting and addressing mental health issues. Major trends in the forecast period include advances in diagnostic methods leading to early detection, the rise of telemedicine facilitates, advances in drug delivery systems, AI and machine learning are increasingly used in drug discovery and development, and developments in pharmacogenomics.

The increasing incidence of mental health disorders is anticipated to drive the expansion of the fluoxetine market in the future. Mental health disorders encompass a wide spectrum of conditions affecting cognitive, emotional, and behavioral functions, resulting in distress or impairment in daily life. Factors contributing to the rise in these disorders include societal pressures, economic challenges, lifestyle shifts, and improved awareness and diagnosis. Fluoxetine is utilized in the treatment of mental health disorders because it alleviates symptoms by enhancing serotonin levels in the brain, crucial for regulating mood and emotions. For example, a survey conducted in November 2022 by the National Health Service, a UK government-funded healthcare system, revealed that approximately 18.0% of children aged 7 to 16 and 22.0% of young individuals aged 17 to 24 potentially had a mental disorder in 2022. Specifically, the prevalence of likely mental disorders among young people aged 17 to 19 increased from 17.4% in 2021 to 25.7% in 2022. Consequently, the rising prevalence of mental health disorders is a significant factor propelling the growth of the fluoxetine market.

The fluoxetine market is anticipated to experience growth due to the rise in healthcare expenditure. This increase is driven by factors such as the escalating costs of advanced medical technologies, aging populations, and the prevalence of chronic diseases. As healthcare spending rises, it improves the accessibility and affordability of medications such as fluoxetine, which benefits patients requiring treatment for depression and anxiety disorders by enhancing access and adherence. Consequently, this can lead to better mental health outcomes overall and reduce long-term healthcare expenses. For example, in January 2024, healthcare expenditure in the US surged by 4.1% in 2022 to $4.5 trillion, marking a faster growth rate compared to the 3.2% increase seen in 2021, as reported by the National Institutes of Health, a US government agency.

Key players in the fluoxetine market are concentrating on innovating products such as fluoxetine tablets for treating various mental health disorders such as major depressive disorder. Fluoxetine tablets contain fluoxetine hydrochloride, an antidepressant classified as a selective serotonin reuptake inhibitor (SSRI). In April 2024, Strides Pharma Global Pte. Limited, a Singapore-based pharmaceutical company, received approval from the United States Food and Drug Administration (USFDA) for Fluoxetine Tabs 10 mg and 20 mg. This approval expands the company's fluoxetine product line by introducing tablets alongside the already-approved capsules. Fluoxetine, an SSRI, is used to treat conditions such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), bulimia nervosa, and panic disorder with or without agoraphobia. The introduction of fluoxetine tablets broadens the treatment options within the company's fluoxetine portfolio, providing patients and healthcare providers with more flexibility and choices in managing these mental health disorders.

Major companies operating in the fluoxetine market are Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Hetero Ltd., Torrent Pharmaceuticals GmbH, Aurobindo Pharma, Cadila Pharmaceuticals Ltd., Dr. Reddy's Laboratories Limited, Apotex Inc., Amneal Pharmaceuticals Inc., Lupin Ltd., Glenmark Pharmaceuticals Inc., Alvogen, Alembic Pharmaceuticals Limited, Accord Healthcare Ltd., PERRIGO Company plc, Wockhardt Ltd., Jubilant Life Sciences Ltd., Lannett Company Inc., Mayne Pharma International Pty Ltd., Par Pharmaceutical Companies Inc., Zydus Pharmaceuticals USA Inc., Ascend Laboratories LLC

North America was the largest region in the fluoxetine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fluoxetine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the fluoxetine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fluoxetine market consists of sales of fluoxetine hydrochloride tablets, fluoxetine powder, and fluoxetine injection. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fluoxetine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on fluoxetine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for fluoxetine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fluoxetine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Fluoxetine Market Characteristics

3. Fluoxetine Market Trends And Strategies

4. Fluoxetine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Fluoxetine Growth Analysis And Strategic Analysis Framework

6. Fluoxetine Market Segmentation

7. Fluoxetine Market Regional And Country Analysis

8. Asia-Pacific Fluoxetine Market

9. China Fluoxetine Market

10. India Fluoxetine Market

11. Japan Fluoxetine Market

12. Australia Fluoxetine Market

13. Indonesia Fluoxetine Market

14. South Korea Fluoxetine Market

15. Western Europe Fluoxetine Market

16. UK Fluoxetine Market

17. Germany Fluoxetine Market

18. France Fluoxetine Market

19. Italy Fluoxetine Market

20. Spain Fluoxetine Market

21. Eastern Europe Fluoxetine Market

22. Russia Fluoxetine Market

23. North America Fluoxetine Market

24. USA Fluoxetine Market

25. Canada Fluoxetine Market

26. South America Fluoxetine Market

27. Brazil Fluoxetine Market

28. Middle East Fluoxetine Market

29. Africa Fluoxetine Market

30. Fluoxetine Market Competitive Landscape And Company Profiles

31. Fluoxetine Market Other Major And Innovative Companies

32. Global Fluoxetine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Fluoxetine Market

34. Recent Developments In The Fluoxetine Market

35. Fluoxetine Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â